C4 Therapeutics, Inc.
CCCC
$1.54
$0.042.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 71.44% | 65.45% | 83.26% | -26.34% | -33.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 71.44% | 65.45% | 83.26% | -26.34% | -33.25% |
| Cost of Revenue | -6.01% | -8.01% | -11.95% | -7.86% | -0.11% |
| Gross Profit | 22.59% | 23.33% | 26.74% | 2.48% | -11.76% |
| SG&A Expenses | 0.10% | -0.55% | -1.24% | 1.25% | -1.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.40% | -6.04% | -9.20% | -5.55% | -0.52% |
| Operating Income | 15.72% | 16.44% | 19.45% | 1.35% | -7.33% |
| Income Before Tax | 19.84% | 21.43% | 23.78% | 4.98% | -2.37% |
| Income Tax Expenses | -89.77% | -72.38% | -- | -- | -- |
| Earnings from Continuing Operations | 20.51% | 21.81% | 22.87% | 4.01% | -3.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.51% | 21.81% | 22.87% | 4.01% | -3.37% |
| EBIT | 15.72% | 16.44% | 19.45% | 1.35% | -7.33% |
| EBITDA | 15.89% | 16.53% | 19.60% | 1.26% | -7.27% |
| EPS Basic | 43.20% | 38.03% | 33.45% | 11.52% | -1.76% |
| Normalized Basic EPS | 43.04% | 37.81% | 35.17% | 12.95% | -3.03% |
| EPS Diluted | 43.20% | 38.11% | 33.53% | 11.64% | -1.58% |
| Normalized Diluted EPS | 43.04% | 37.81% | 35.17% | 12.95% | -3.03% |
| Average Basic Shares Outstanding | 39.74% | 31.51% | 21.29% | 11.35% | 1.59% |
| Average Diluted Shares Outstanding | 39.74% | 31.51% | 21.29% | 11.35% | 1.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |